Skip to main content

Advertisement

Fig. 1 | BMC Cancer

Fig. 1

From: Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)

Fig. 1

Heat map of molecular alterations among 133 metastatic colorectal cancer patients. In 28 patients included in the KRAS Registry of the Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT), at least one molecular analysis of KRAS, NRAS, BRAF, PI3K and/or TP53 was missing, therefore these patients were excluded from the illustration

Back to article page